Pharmacogenetic tests, along with other information about patients and their disease or condition, can play an important role in drug therapy. When a health care provider is considering prescribing a drug, knowledge of a patient’s genotype may be used to aid in determining a therapeutic strategy, determining an appropriate dosage, or assessing the likelihood of benefit or toxicity.

PharmGKB is a comprehensive resource that curates knowledge about the impact of genetic variation on drug response for clinicians and researchers. It is funded by the NIH. https://www.pharmgkb.org

PharmGKB — coalition of educational resources: https://www.pharmgkb.org/page/educationalResources

The Clinical Pharmacogenetics Implementation Consortium (CPIC) is an international consortium of individual volunteers including physicians, and pharmacists based out of St. Jude and Stanford who are interested in facilitating the use of pharmacogenetic tests for patient care. https://cpicpgx.org

FDA — Table of Pharmacogenomic Biomarkers in Drug Labeling lists therapeutic products with pharmacogenomic information found in the drug labeling. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling

FDA — Table of PGx Associations. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations

PREPARE Study — The 2023 PREPARE Study, which included over 6,000 patients and a multi-gene panel, showed that adverse drug reactions were reduced by around 30% when certain prescriptions were informed by PGx test results. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01841-4/abstract